As of 2025-07-12, the EV/EBITDA ratio of BridgeBio Pharma Inc (BBIO) is -15.91. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BridgeBio's latest enterprise value is 10,628.54 mil USD. BridgeBio's TTM EBITDA according to its financial statements is -668.13 mil USD. Dividing these 2 quantities gives us the above BridgeBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.3x - 14.3x | 10.9x |
| Forward P/E multiples | 12.3x - 15.0x | 13.4x |
| Fair Price | (52.64) - (59.96) | (52.35) |
| Upside | -213.3% - -229.0% | -212.6% |
| Date | EV/EBITDA |
| 2025-07-11 | -15.91 |
| 2025-07-10 | -15.85 |
| 2025-07-09 | -15.77 |
| 2025-07-08 | -14.98 |
| 2025-07-07 | -15.06 |
| 2025-07-03 | -15.20 |
| 2025-07-02 | -14.87 |
| 2025-07-01 | -14.86 |
| 2025-06-30 | -14.97 |
| 2025-06-27 | -15.45 |
| 2025-06-26 | -15.52 |
| 2025-06-25 | -15.31 |
| 2025-06-24 | -15.33 |
| 2025-06-23 | -14.69 |
| 2025-06-20 | -14.56 |
| 2025-06-18 | -14.07 |
| 2025-06-17 | -14.09 |
| 2025-06-16 | -14.39 |
| 2025-06-13 | -14.01 |
| 2025-06-12 | -13.97 |
| 2025-06-11 | -13.80 |
| 2025-06-10 | -14.09 |
| 2025-06-09 | -13.79 |
| 2025-06-06 | -13.68 |
| 2025-06-05 | -13.60 |
| 2025-06-04 | -13.51 |
| 2025-06-03 | -13.36 |
| 2025-06-02 | -12.78 |
| 2025-05-30 | -12.44 |
| 2025-05-29 | -12.18 |
| 2025-05-28 | -11.87 |
| 2025-05-27 | -12.11 |
| 2025-05-23 | -12.18 |
| 2025-05-22 | -12.07 |
| 2025-05-21 | -12.03 |
| 2025-05-20 | -12.28 |
| 2025-05-19 | -12.28 |
| 2025-05-16 | -12.32 |
| 2025-05-15 | -12.29 |
| 2025-05-14 | -12.27 |
| 2025-05-13 | -12.15 |
| 2025-05-12 | -12.84 |
| 2025-05-09 | -12.41 |
| 2025-05-08 | -12.61 |
| 2025-05-07 | -12.88 |
| 2025-05-06 | -13.20 |
| 2025-05-05 | -13.56 |
| 2025-05-02 | -13.66 |
| 2025-05-01 | -13.61 |
| 2025-04-30 | -13.60 |